Reuters logo
4 个月前
BRIEF-First dedicated outcome trials of empagliflozin in chronic heart failure initiated
2017年3月17日 / 下午12点53分 / 4 个月前

BRIEF-First dedicated outcome trials of empagliflozin in chronic heart failure initiated

1 分钟阅读

March 17 (Reuters) - Eli Lilly And Co

* First dedicated outcome trials of Empagliflozin in chronic heart failure initiated

* Emperor HF comprises two phase III outcome studies that will investigate empagliflozin for treatment of adults with chronic heart failure

* Trials will involve not only adults with type 2 diabetes who have heart failure, but also heart failure patients who do not have diabetes

* Emperor HF's two trials will involve approximately 7,000 patients in total and are anticipated to complete in 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below